Brainstorm Cell Therapeutics Inc. (BCLI) — SEC Filings
Brainstorm Cell Therapeutics Inc. (BCLI) — 43 SEC filings. Latest: 10-Q (Nov 14, 2025). Includes 30 8-K, 6 10-Q, 2 DEF 14A.
View Brainstorm Cell Therapeutics Inc. on SEC EDGAR
Overview
Brainstorm Cell Therapeutics Inc. (BCLI) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 14, 2025: BRAINSTORM CELL THERAPEUTICS INC. (BCLI) reported a net loss of $2.106 million for the three months ended September 30, 2025, an improvement from a net loss of $2.708 million in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $7.873 million, compared to $8.650
Sentiment Summary
Across 43 filings, the sentiment breakdown is: 9 bearish, 34 neutral. The dominant filing sentiment for Brainstorm Cell Therapeutics Inc. is neutral.
Filing Type Overview
Brainstorm Cell Therapeutics Inc. (BCLI) has filed 6 10-Q, 30 8-K, 2 DEF 14A, 2 10-K, 2 SC 13G, 1 SC 13G/A with the SEC between Feb 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (43)
Risk Profile
Risk Assessment: Of BCLI's 41 recent filings, 10 were flagged as high-risk, 17 as medium-risk, and 14 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Net Income | -$2.106M |
| EPS | -$0.19 |
| Cash Position | $5K |
| Total Assets | $1.380M |
Key Executives
- Dr. Jonathan R. Mill
- Dr. Arthur S. Tisch
- Ms. Sharon Roth
- Kevin D. Ness
- Canada
Industry Context
Brainstorm Cell Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on cell therapies. This industry is characterized by long development cycles, high R&D costs, significant regulatory hurdles, and the potential for substantial returns upon successful drug commercialization. Companies often rely on external financing and strategic partnerships to fund their research and clinical trials.
Top Tags
delisting (7) · financials (7) · filing (6) · financial-condition (5) · regulatory (5) · governance (4) · 8-k (4) · 10-Q (4) · material-definitive-agreement (3) · equity-sale (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net loss for Q3 2025 | $2.106M | Improved from $2.708M in Q3 2024 |
| Net loss for nine months ended Sep 30, 2025 | $7.873M | Improved from $8.650M in the same period of 2024 |
| Cash and cash equivalents as of Sep 30, 2025 | $5K | Significant decrease from $187K at Dec 31, 2024 |
| Accumulated deficit as of Sep 30, 2025 | $235M | Indicates substantial historical losses and going concern risk |
| Research and development expenses for Q3 2025 | $899K | Decreased from $1.045M in Q3 2024 |
| General and administrative expenses for Q3 2025 | $1.148M | Decreased from $2.003M in Q3 2024 |
| Shares outstanding as of Nov 11, 2025 | 11,034,775 | Increased from 6,141,762 shares at Dec 31, 2024 |
| Basic and diluted net loss per share for nine months ended Sep 30, 2025 | $0.91 | Improved from $1.80 in the same period of 2024 |
| Basic and diluted net loss per share for Q3 2025 | $0.19 | Improved from $0.51 in Q3 2024 |
| Net cash used in operating activities for nine months ended Sep 30, 2025 | $6.235M | Improved from $8.045M in the same period of 2024 |
| Net Loss (Q2 2025) | $2.903M | Increased from $2.541M in Q2 2024 |
| Net Loss (H1 2025) | $5.767M | Slight improvement from $5.942M in H1 2024 |
| Research and Development Expenses (H1 2025) | $2.424M | Increased from $1.883M in H1 2024 |
| General and Administrative Expenses (H1 2025) | $3.238M | Decreased from $3.573M in H1 2024 |
| Cash and Cash Equivalents (June 30, 2025) | $824K | Increased from $187K at December 31, 2024 |
Forward-Looking Statements
- {"claim":"Kevin D. Ness will maintain his significant stake in Brainstorm Cell Therapeutics Inc. for the foreseeable future.","entity":"Kevin D. Ness","targetDate":"2025-02-14","confidence":"medium"}
- {"claim":"The substantial ownership by Kevin D. Ness could lead to increased investor scrutiny on Brainstorm Cell Therapeutics Inc.'s strategic decisions.","entity":"Brainstorm Cell Therapeutics Inc.","targetDate":"2024-08-14","confidence":"medium"}
Frequently Asked Questions
What are the latest SEC filings for Brainstorm Cell Therapeutics Inc. (BCLI)?
Brainstorm Cell Therapeutics Inc. has 43 recent SEC filings from Feb 2024 to Nov 2025, including 30 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of BCLI filings?
Across 43 filings, the sentiment breakdown is: 9 bearish, 34 neutral. The dominant sentiment is neutral.
Where can I find Brainstorm Cell Therapeutics Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Brainstorm Cell Therapeutics Inc. (BCLI) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Brainstorm Cell Therapeutics Inc.?
Key financial highlights from Brainstorm Cell Therapeutics Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for BCLI?
The investment thesis for BCLI includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Brainstorm Cell Therapeutics Inc.?
Key executives identified across Brainstorm Cell Therapeutics Inc.'s filings include Dr. Jonathan R. Mill, Dr. Arthur S. Tisch, Ms. Sharon Roth, Kevin D. Ness, Canada.
What are the main risk factors for Brainstorm Cell Therapeutics Inc. stock?
Of BCLI's 41 assessed filings, 10 were flagged high-risk, 17 medium-risk, and 14 low-risk.
What are recent predictions and forward guidance from Brainstorm Cell Therapeutics Inc.?
Recent forward-looking statements from Brainstorm Cell Therapeutics Inc. include guidance on {"claim":"Kevin D. Ness will maintain his significant stake in Brainstorm Cell Therapeutics Inc. for the foreseeable fut and 1 other predictions.